PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Plasma p-tau217 Discriminates Early-Onset Alzheimer's in Real-World Clinic

This real-world diagnostic study extends plasma p-tau217 validation to early-onset Alzheimer's disease and flags severe renal impairment as a false-positive risk relevant to biomarker interpretation.
plasma p-tau217ALZpathSimoablood biomarkersearly-onset Alzheimer's diseaseEOADneurodegenerative diseasediagnostic accuracyrenal impairmentamyloidtaudementia Neurology / Neuropharmacology
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Chatterjee P, Ivanic S, Southon A, McCarthy C, Patel SK, Christensen M, Darby D, Bush AI, Ayton S, Werden E, Brodtmann A

Citation: Chatterjee P, Ivanic S, Southon A, et al. Real world diagnostic performance of plasma p-tau217 for early-onset Alzheimer's disease in a cognitive disorders tertiary care setting. Journal of Alzheimer's disease : JAD. 2025;108(1):387-396. doi:10.1177/13872877251376694

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →